Buprenorphine tablet versus liquid: A clinical trial comparing plasma levels, efficacy, and symptoms

Journal of Substance Abuse Treatment

Volumn 29, Issue 4, 2005, Pages 307-312

  Chawarski, Marek C ^a   Moody, David E ^b   Pakes, Juliana ^a   O'Connor, Patrick G ^a   Schottenfeld, Richard S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Buprenorphine; Opioid maintenance; Plasma concentration; Substance abuse

Indexed keywords

BUPRENORPHINE; OPIATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TABLET FORMULATION; WITHDRAWAL SYNDROME;

ADMINISTRATION, SUBLINGUAL; ADULT; BUPRENORPHINE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PHARMACEUTICAL SOLUTIONS; SUBSTANCE WITHDRAWAL SYNDROME; TABLETS; TREATMENT OUTCOME;

EID: 28244480218     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2005.08.011     Document Type: Article

References (22)

1. W.K. Bickel, M.L. Stitzer, G.E. Bigelow, I.A. Liebson, D.R. Jasinski, and R.E. Johnson Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans Journal of Pharmacology & Experimental Therapeutics 247 1988 47 53
2. P.J. Fudala, T.P. Bridge, S. Herbert, W.O. Williford, C.N. Chiang, and K. Jones Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone New England Journal of Medicine 349 2003 949 958
3. D.S. Harris, J.E. Mendelson, E.T. Lin, R.A Upton, and R.T. Jones Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: Lack of dose proportionality Clinical Pharmacokinetics 43 2004 329 340
4. R.E. Johnson, M.A. Chutuape, E.C. Strain, S.L. Walsh, M.L. Stitzer, and G.E. Bigelow A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence New England Journal of Medicine 343 2000 1290 1297
5. R.E. Johnson, J.H. Jaffe, and P.J. Fudala A controlled trial of buprenorphine treatment for opioid dependence JAMA 267 1992 2750 2755
6. T.R. Kosten, R. Schottenfeld, D. Ziedonis, and J. Falcioni Buprenorphine versus methadone maintenance for opioid dependence Journal of Nervous & Mental Disease 181 1993 358 364
7. J.J. Kuhlman, S. Lalani, J. Magluilo, B. Levine, W.D. Darwin, and R.E. Johnson Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine Journal of Analytical Toxicology 20 1996 369 378
8. J.J. Kuhlman, B. Levine, R.E. Johnson, P.J. Fudala, and E.J. Cone Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine Addiction 93 1998 549 559
9. W. Ling, C. Charuvastra, J.F. Collins, S. Batki, L.S. Brown Jr, and P. Kintaudi Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial Addiction 93 1998 475 486
10. R.P. Mattick, J. Kimber, C. Breen, and M. Davoli Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence Cochrane Database of Systematic Reviews 2002 CD002207
11. P. McGettigan, D.A. Henry, and S. Hennesy Basic principles of clinical pharmacology relevant to pharmacoepidemiology studies B.L. Storm Pharmacoepidemiology 2000 Wiley & Sons New York
12. N.K. Mello, and J.H. Mendelson Buprenorphine suppresses heroin use by heroin addicts Science 207 1980 657 659
13. J. Mendelson, R.A. Upton, E.T. Everhart, P. Jacob III, and R.T. Jones Bioavailability of sublingual buprenorphine Journal of Clinical Pharmacology 37 1997 31 37
14. J. Mendelson, R.A. Upton, and R.T. Jones Buprenorphine pharmacokinetics: Bioavailability of an 8 mg sublingual tablet formulation L.S. Harris III Problems of Drug Dependence 1995: Proceedings of the 57th Annual Scientific Meeting, NIDA Research Monograph Series #162 1996 US Government Printing Office Washington, DC 112
15. D.E. Moody, M.H. Slawson, E.C. Strain, J.D. Laycock, A.C. Spanbauer, and R.L. Foltz A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies Analytical Biochemistry 306 2002 31 39
16. R.P. Nath, R.A. Upton, E.T. Everhart, P. Cheung, P. Shwonek, and R.T. Jones Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tables and liquid formulations Journal of Clinical Pharmacology 39 1999 619 623
17. P.G. O'Connor, M.C. Chawarski, J. Pakes, and R.S. Schottenfeld A pilot study of three dose schedules for thrice-weekly administration of buprenorphine Problems of Drug Dependence 1997: Proceedings of the 59th Annual Scientific Meeting 1998 (NIDA Research Monograph 178)
18. R.S. Schottenfeld, J. Pakes, P. O'Connor, M.C. Chawarski, A. Oliveto, and T.R. Kosten Thrice-weekly versus daily buprenorphine maintenance Biological Psychiatry 47 2000 1072 1079
19. R.S. Schottenfeld, J.R. Pakes, A. Oliveto, D. Ziedonis, and T.R. Kosten Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse Archives of General Psychiatry 54 1997 713 720
20. K.J. Schuh, and C.E. Johanson Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet Drug and Alcohol Dependence 56 1999 55 60
21. E.C. Strain, D.E. Moody, K.B. Stoller, S.L. Walsh, and G.E. Bigelow Relative bioavailability of different buprenorphine formulations under chronic dosing conditions Drug and Alcohol Dependence 74 2004 37 43
22. E.C. Strain, M.L. Stitzer, I.A. Liebson, and G.E. Bigelow Comparison of buprenorphine and methadone in the treatment of opioid dependence American Journal of Psychiatry 151 1994 1025 1030